Hepatitis C and metabolic syndrome

References

• Ge D, Fellay J, Thompson AJ et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature461(7262), 399–401 (2009).
   PubMed Web of Science ®Google Scholar
• Bressler BL, Guindi M, Tomlinson G, Heathcote J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology38(3), 639–644 (2003).
   PubMed Web of Science ®Google Scholar
• Tarantino G, Conca P, Sorrentino P, Ariello M. Metabolic factors involved in the therapeutic response of patients with hepatitis C virus-related chronic hepatitis. J. Gastroenterol. Hepatol.21, 1266–1268 (2006).
   PubMedGoogle Scholar
• Elgouhari HM, Zein CO, Hanouneh I, Feldstein AE, Zein NN. Diabetes mellitus is associated with impaired response to antiviral therapy in chronic hepatitis C infection. Dig. Dis. Sci. DOI: 10.1007/s10620-008-0683-2 (2009) (Epub ahead of print).
   PubMedGoogle Scholar
• Younossi ZM, McCullough AJ. Metabolic syndrome, non-alcoholic fatty liver disease and hepatitis C virus: impact on disease progression and treatment response. Liver Int.29(Suppl. 2), 3–12 (2009).
   PubMedGoogle Scholar
• Tarantino G, Conca P, Ariello M, Mastrolia M. Does a lower insulin resistance affect antiviral therapy response in patients suffering from HCV related chronic hepatitis? Gut55(4), 585 (2006).
   PubMed Web of Science ®Google Scholar
• Butt AA, Wang X, Moore CG. Effect of hepatitis C virus and its treatment on survival. Hepatology50(2), 387–392 (2009).
   PubMedGoogle Scholar
• Adinolfi LE, Utili R, Andreana A et al. Serum HCV RNA levels correlate with histological liver damage and concur with steatosis in progression of chronic hepatitis C. Dig. Dis. Sci.46(8), 1677–1683 (2001).
   PubMedGoogle Scholar
• Tarantino G, Saldalamacchia G, Conca P, Arena A. Non-alcoholic fatty liver disease: further expression of the metabolic syndrome. J. Gastroenterol. Hepatol.22(3), 293–303 (2007).
   PubMed Web of Science ®Google Scholar
• Zekry A, McHutchison JG, Diehl AM. Insulin resistance and steatosis in hepatitis C virus infection. Gut54(7), 903–906 (2005).
   PubMed Web of Science ®Google Scholar
• Cammà C, Bruno S, Di Marco V et al. Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. Hepatology43(1), 64–71 (2006).
   PubMed Web of Science ®Google Scholar
• Qiang G, Yang L, Witek RP, Jhaveri R. Recombinant adenoviruses expressing steatosis-associated hepatitis C virus genotype 3 core protein produce intracellular lipid accumulation in cultured and primary hepatocytes. Virus Res.139(1), 127–130 (2009).
   PubMedGoogle Scholar
• Sheikh MY, Choi J, Qadri I, Friedman JE, Sanyal AJ. Hepatitis C virus infection: molecular pathways to metabolic syndrome. Hepatology47(6), 2127–2133 (2008).
   PubMed Web of Science ®Google Scholar
• Grigorescu M, Radu C, Crişan D et al. Metabolic syndrome, insulin resistance and adiponectin level in patients with chronic hepatitis C. J. Gastrointestin. Liver Dis.17(2), 147–154 (2008).
   PubMed Web of Science ®Google Scholar
• Hourioux C, Patient R, Morin A et al. The genotype 3-specific hepatitis C virus core protein residue phenylalanine 164 increases steatosis in an in vitro cellular model. Gut56(9), 1302–1308 (2007).
   PubMed Web of Science ®Google Scholar
• Ong JP, Elariny H, Collantes R et al. Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients. Obes. Surg.15(3), 310–315 (2005).
   PubMed Web of Science ®Google Scholar
• Hui JM, Kench J, Farrell GC et al. Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infection. J. Gastroenterol. Hepatol.17(8), 873–881 (2002).
   PubMed Web of Science ®Google Scholar
• Mehta SH, Brancati FL, Strathdee SA et al. Hepatitis C virus infection and incident Type 2 diabetes. Hepatology38(1), 50–56 (2003).
   PubMed Web of Science ®Google Scholar
• Ozdemir O, Arda K, Soylu M, Alyan O, Demir AD, Kütük E. Seroprevalence of hepatitis B and C in subjects admitted to a cardiology clinics in Turkey. Eur. J. Epidemiol.18(3), 255–258 (2003).
   PubMedGoogle Scholar
• Hui CK, Belaye T, Montegrande K, Wright TL. A comparison in the progression of liver fibrosis in chronic hepatitis C between persistently normal and elevated transaminase. J. Hepatol.38(4), 511–517 (2003).
   PubMed Web of Science ®Google Scholar
• Cua IH, Hui JM, Kench JG, George J. Genotype-specific interactions of insulin resistance, steatosis, and fibrosis in chronic hepatitis C. Hepatology48(3), 723–731 (2008).
   PubMed Web of Science ®Google Scholar
• Moucari R, Asselah T, Cazals-Hatem D et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology134(2), 416–423 (2008).
   PubMed Web of Science ®Google Scholar
• Almeda-Valdés P, Cuevas-Ramos D, Aguilar-Salinas CA. Metabolic syndrome and non-alcoholic fatty liver disease. Ann. Hepatol.8(Suppl. 1), S18–S24 (2009).
   PubMed Web of Science ®Google Scholar
• Day CP. The potential role of genes in nonalcoholic fatty liver disease. Clin. Liver Dis.8(3), 673–691 (2004).
   PubMedGoogle Scholar
• Mason AL, Lau JY, Hoang N et al. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology29(2), 328–333 (1999).
   PubMed Web of Science ®Google Scholar
• Chen HF, Li CY, Chen P, See TT, Lee HY. Seroprevalence of hepatitis B and C in Type 2 diabetic patients. J. Chin. Med. Assoc.69(4), 146–152 (2006).
   PubMedGoogle Scholar
• Lecube A, Hernández C, Genescà J, Esteban JI, Jardí R, Simó R. High prevalence of glucose abnormalities in patients with hepatitis C virus infection: a multivariate analysis considering the liver injury. Diabetes Care27(5), 1171–1175 (2004).
   PubMed Web of Science ®Google Scholar
• Shintani Y, Fujie H, Miyoshi H et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology126(3), 840–848 (2004).
   PubMed Web of Science ®Google Scholar
• Dharancy S, Malapel M, Perlemuter G et al. Impaired expression of the peroxisome proliferator-activated receptor α during hepatitis C virus infection. Gastroenterology128(2), 334–342 (2005).
   PubMed Web of Science ®Google Scholar
• Im SS, Kwon SK, Kim TH, Kim HI, Ahn YH. Regulation of glucose transporter type 4 isoform gene expression in muscle and adipocytes. IUBMB Life59(3), 134–145 (2007).
   PubMed Web of Science ®Google Scholar
• Petit JM, Minello A, Jooste V et al. Decreased plasma adiponectin concentrations are closely related to steatosis in hepatitis C virus-infected patients. J. Clin. Endocrinol. Metab.90(4), 2240–2243 (2005).
   PubMed Web of Science ®Google Scholar
• Kovac IP, Havlik RJ, Foley D et al. Linkage and association analyses of Type 2 diabetes/impaired glucose metabolism and adiponectin serum levels in Japanese Americans from Hawaii. Diabetes56(2), 537–540 (2007).
   PubMedGoogle Scholar
• Sanyal AJ, Campbell-Sargent C et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology120(5), 1183–1192 (2001).
   PubMed Web of Science ®Google Scholar
• Machida K, Cheng KT, Lai CK, Jeng KS, Sung VM, Lai MM. Hepatitis C virus triggers mitochondrial permeability transition with production of reactive oxygen species, leading to DNA damage and STAT3 activation. J. Virol.80(14), 7199–7207 (2006).
   PubMedGoogle Scholar
• Begriche K, Igoudjil A, Pessayre D, Fromenty B. Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion6(1), 1–28 (2006).
   PubMed Web of Science ®Google Scholar
• Jaeschke H. Reactive oxygen and mechanisms of inflammatory liver injury. J. Gastroenterol. Hepatol.15(7), 718–724 (2000).
   PubMed Web of Science ®Google Scholar
• Wellen KE, Hotamisligil GS. Obesity-induced inflammatory changes in adipose tissue. J. Clin. Invest.112(12), 1785–1788 (2003).
   PubMed Web of Science ®Google Scholar
• Bahcecioglu IH, Yalniz M, Ataseven H et al. Levels of serum hyaluronic acid, TNF-α and IL-8 in patients with nonalcoholic steatohepatitis. Gastroenterol. Hepatol.52(65), 1549–1553 (2005).
   Google Scholar
• Cua IH, Hui JM, Bandara P et al. Insulin resistance and liver injury in hepatitis C is not associated with virus-specific changes in adipocytokines. Hepatology46(1), 66–73 (2007).
   PubMed Web of Science ®Google Scholar
• Cheung O, Puri P, Eicken C et al. Nonalcoholic steatohepatitis is associated with altered hepatic microRNA expression. Hepatology48(6), 1810–1820 (2008).
   PubMed Web of Science ®Google Scholar
• Chen XM. MicroRNA signatures in liver diseases. World J. Gastroenterol.15(14), 1665–1672 (2009).
   PubMed Web of Science ®Google Scholar
• Ura S, Honda M, Yamashita T et al. Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma. Hepatology49(4), 1098–1112 (2009).
   PubMed Web of Science ®Google Scholar
• Hui JM, Kench JG, Chitturi S et al. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology38(2), 420–427 (2003).
   PubMed Web of Science ®Google Scholar
• Paradis V, Zalinski S, Chelbi E et al. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology49(3), 851–859 (2009).
   PubMed Web of Science ®Google Scholar
• Browning JD, Szczepaniak LS, Dobbins R et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology40, 1387–1395 (2004).
   PubMed Web of Science ®Google Scholar
• Browning JD, Kumar KS, Saboorian MH, Thiele DL. Ethnic differences in the prevalence of cryptogenic cirrhosis. Am. J. Gastroenterol.99, 292–298 (2004).
   PubMed Web of Science ®Google Scholar
• Romeo S, Kozlitina J, Xing C et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet.40(12), 1461–1465 (2008).
   PubMed Web of Science ®Google Scholar
• Whitt K, Fleckenstein J. Hepatitis C in African Americans. Curr. Hepat. Rep.7(4), 139–144 (2008).
   Google Scholar
• Conjeevaram HS, Fried MW, Jeffers LJ et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology131(2), 470–477 (2006).
   PubMed Web of Science ®Google Scholar
• Neuschwander-Tetri BA. Fatty liver and the metabolic syndrome. Curr. Opin. Gastroenterol.23(2), 193–198 (2007).
   PubMedGoogle Scholar
• Machado M, Cortez-Pinto H. Non-alcoholic steatohepatitis and metabolic syndrome. Curr. Opin. Clin. Nutr. Metab. Care.9(5), 637–642 (2006).
   PubMed Web of Science ®Google Scholar
• Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology43(2 Suppl. 1), S99–S112 (2006).
   PubMed Web of Science ®Google Scholar
• Collantes R, Ong JP, Younossi ZM. Nonalcoholic fatty liver disease and the epidemic of obesity. Cleve. Clin. J. Med.71(8), 657–664 (2004).
   PubMedGoogle Scholar
• Ong JP, Younossi ZM. Epidemiology and natural history of NAFLD and NASH. Clin. Liver Dis.11(1), 1–16, vii (2007).
   PubMedGoogle Scholar
• Rafiq N, Younossi ZM. Interaction of metabolic syndrome, nonalcoholic fatty liver disease and chronic hepatitis C. Expert Rev. Gastroenterol. Hepatol.2(2), 207–215 (2008).
   PubMedGoogle Scholar
• Charlton MR, Pockros PJ, Harrison SA. Impact of obesity on treatment of chronic hepatitis C. Hepatology43(6), 1177–1186 (2006).
   PubMed Web of Science ®Google Scholar
• Chen W, Wong T, Tomlinson G, Krahn M, Heathcote EJ. Prevalence and predictors of obesity among individuals with positive hepatitis C antibody in a tertiary referral clinic. J. Hepatol.49(5), 711–717 (2008).
   PubMed Web of Science ®Google Scholar
• Puri P, Sanyal AJ. Role of obesity, insulin resistance, and steatosis in hepatitis C virus infection. Clin. Liver Dis.10(4), 793–819 (2006).
   PubMedGoogle Scholar
• Glue P, Fang JWS, Rouzier-Panis R et al. Pegylated interferon-α2β: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy group. Clin. Pharmacol. Ther.68, 556–567 (2000).
   PubMed Web of Science ®Google Scholar
• Lamb MW, Martin NE. Weight-based versus fixed dosing of peginterferon (40kDa) α-2a. Ann. Pharmacother.36, 933–935 (2002).
   PubMed Web of Science ®Google Scholar
• Mccullough AJ. Obesity and its nurturing effect on hepatitis C. Hepatology38, 557–559 (2003).
   PubMedGoogle Scholar
• Jacobson IM, Brown RS, Freilich B et al. Weight-based ribavirin dosing increases sustained viral response in patients with chronic hepatitis C: final results of the WIN-R study, a US community based trial. Hepatology42(Suppl. 1), 749A (2005).
   PubMed Web of Science ®Google Scholar
• Jacobson IM, Brown RS Jr, McCone J et al. Impact of weight-based ribavirin with peginterferon α-2b in African Americans with hepatitis C virus genotype 1. Hepatology46(4), 982–990 (2007).
   PubMed Web of Science ®Google Scholar
• Baranova A, Gowder SJ, Schlauch K et al. Gene expression of leptin, resistin, and adiponectin in the white adipose tissue of obese patients with non-alcoholic fatty liver disease and insulin resistance. Obes. Surg.16(9), 1118–1125 (2006).
   PubMed Web of Science ®Google Scholar
• Schäffler A, Müller-Ladner U, Schölmerich J, Büchler C. Role of adipose tissue as an inflammatory organ in human diseases. Endocr. Rev.27(5), 449–467 (2006).
   PubMed Web of Science ®Google Scholar
• Lee SA, Kallianpur A, Xiang YB et al. Intra-individual variation of plasma adipokine levels and utility of single measurement of these biomarkers in population-based studies. Cancer Epidemiol. Biomarkers Prev.16(11), 2464–2470 (2007).
   PubMed Web of Science ®Google Scholar
• Estep JM, Baranova A, Hossain N et al. Expression of cytokine signaling genes in morbidly obese patients with non-alcoholic steatohepatitis and hepatic fibrosis. Obes. Surg.19(5), 617–624 (2009).
   PubMed Web of Science ®Google Scholar
• Pradhan A. Obesity, metabolic syndrome, and Type 2 diabetes: inflammatory basis of glucose metabolic disorders. Nutr. Rev.65(12 Pt 2), S152–S156 (2007).
   PubMed Web of Science ®Google Scholar
• Dyck DJ. Adipokines as regulators of muscle metabolism and insulin sensitivity. Appl. Physiol. Nutr. Metab.34(3), 396–402 (2009).
   PubMed Web of Science ®Google Scholar
• Park PH, Thakur V, Pritchard MT, McMullen MR, Nagy LE. Regulation of Kupffer cell activity during chronic ethanol exposure: role of adiponectin. J. Gastroenterol. Hepatol.21(Suppl. 3), S30–S33 (2006).
   Google Scholar
• Kajikawa S, Harada T, Kawashima A, Imada K, Mizuguchi K. Suppression of hepatic fat accumulation by highly purified eicosapentaenoic acid prevents the progression of D-galactosamine-induced hepatitis in mice fed with a high-fat/high-sucrose diet. Biochim. Biophys. Acta1791(4), 281–288 (2009).
   PubMedGoogle Scholar
• Akifusa S, Kamio N, Shimazaki Y, Yamaguchi N, Nishihara T, Yamashita Y. Globular adiponectin-induced RAW 264 apoptosis is regulated by a reactive oxygen species-dependent pathway involving Bcl-2. Free Radic. Biol. Med.46(9), 1308–1316 (2009).
   PubMedGoogle Scholar
• Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology134(6), 1655–1669 (2008).
   PubMed Web of Science ®Google Scholar
• Romero-Gómez M, Del Mar Viloria M et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology128(3), 636–641 (2005).
   PubMed Web of Science ®Google Scholar
• Lecube A, Hernández C, Simó R, Esteban JI, Genescà J. Glucose abnormalities are an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Am. J. Gastroenterol.102(10), 2189–2195 (2007).
   PubMedGoogle Scholar
• Armstrong GL, Wasley A, Simard EP et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann. Intern. Med.144, 705–714 (2006).
   PubMed Web of Science ®Google Scholar
• Haluzík M, Parízková J, Haluzík MM. Adiponectin and its role in the obesity-induced insulin resistance and related complications. Physiol. Res.53(2), 123–129 (2004).
   PubMed Web of Science ®Google Scholar
• Lecube A, Hernández C, Genescà J, Simó R. Proinflammatory cytokines, insulin resistance, and insulin secretion in chronic hepatitis C patients: a case–control study. Diabetes Care29(5), 1096–1101 (2006).
   PubMed Web of Science ®Google Scholar
• Bataller R, Paik YH, Lindquist JN, Lemasters JJ, Brenner DA. Hepatitis C virus core and nonstructural proteins induce fibrogenic effects in hepatic stellate cells. Gastroenterology126, 529–540 (2004).
   PubMed Web of Science ®Google Scholar
• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA285(19), 2486–2497 (2001).
   PubMed Web of Science ®Google Scholar